Brought to you by:
PROMISE II 12-month data show durable outcomes with the LimFlow system in no-option CLTI patients
One-year results from the PROMISE II US pivotal trial demonstrate the durability of outcomes of transcatheter arterialisation of the deep veins (TADV) using the LimFlow system (LimFlow) and that the procedure is safe and reproducible. Daniel Clair (Vanderbilt University Medical…
The top 10 most popular Vascular Specialist stories of October 2023
Last month, the most popular stories from Vascular Specialist included The Centers for Medicare & Medicaid Services (CMS) confirmation of carotid artery stenting coverage expansion; data on a “next generation” inferior vena cava (IVC) filter retrieval device presented at the annual…
LimFlow announces agreement to be acquired by Inari Medical
LimFlow announced today that it has entered into a definitive agreement to be acquired by Inari Medical. A press release details that, under the terms of the agreement, LimFlow will receive US$250 million in cash at closing and be eligible…
CLTI: European cohort study provides ‘strong positive evidence’ for surgery over endovascular approach, supporting BEST-CLI results
A recently published study has shown that lower limb bypass surgery offered a significantly higher probability of amputation-free survival and wound healing compared with endovascular treatment in patients with chronic limb-threatening ischemia (CLTI). This and other key findings from the…
TCT 2023: LIFE-BTK breathes life into drug-eluting resorbable scaffolds in breakthrough for below-the-knee arteries
Results of the LIFE-BTK randomized controlled trial have just been presented at TCT 2023 (Oct. 23–26) in San Francisco. The data show that, in patients with chronic limb-threatening ischemia (CLTI) due to infrapopliteal artery disease, an everolimus-eluting resorbable scaffold was…
MVSS 2023: Human Acellular Vessel proves ‘safe, effective bypass conduit’ in complex CLTI cohort
An investigator-sponsored clinical study conducted at the Mayo Clinic in Rochester, Minnesota, of the investigational Human Acellular Vessel (HAV) in patients with chronic limb-threatening ischemia (CLTI) was presented at the Midwestern Vascular Surgical Society (MVSS) annual meeting in Minneapolis, Minnesota…
The top 10 most popular Vascular Specialist stories of September 2023
Last month, the most read stories from Vascular Specialist included data releases from the recent Midwestern Vascular Surgical Society (MVSS) using direct revascularization of segmental arteries to prevent spinal cord ischemia; a reflection on the crucial role of vascular nurses during…
When women are PIs: A story foretold on the vascular frontlines
“Multifactorial” issues persist in gender representation in vascular leadership and trial enrollment, leading women vascular surgeons tell Vascular Specialist. “We would have fewer untoward side effects, fewer drugs removed from the market by the FDA [Food and Drug Administration], and,…
FDA approves LimFlow system for ‘no-option’ CLTI patients
The Food and Drug Administration (FDA) today announced approval of LimFlow therapy—a novel and minimally invasive procedure designed to bypass blockages in arteries of the legs and restore blood flow for many thousands of people suffering from chronic limb-threatening ischemia…
SVS responds to New York Times article on overuse of vascular interventions
In an official Society response, SVS President Joseph Mills, MD, tackles recent coverage in the mainstream media of inappropriateness in vascular care. There have been several recently published articles by respected news media outlets highlighting the deeply concerning issue of…